Related Experiment Video
Updated: Jun 8, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations
Derek J Hausenloy1, Gary Baxter, Robert Bell
1The Hatter Cardiovascular Institute, University College London Hospitals and Medical School, 67 Chenies Mews, London, WC1E 6HX, UK.
Insights
Developing effective cardioprotective strategies for ischemic heart disease (IHD) requires improved preclinical and clinical study designs. These Hatter Workshop Recommendations aim to enhance the translation of novel IHD treatments to patient benefit.
Area of Science:
- Cardiovascular Research
- Translational Medicine
- Cardioprotection
Background:
- Ischemic heart disease (IHD) remains the leading global cause of mortality.
- Despite numerous laboratory discoveries, translating cardioprotective strategies into clinical practice has been largely unsuccessful.
- Key barriers include inadequate animal models for ischemia-reperfusion injury and flawed clinical study designs.
Framework:
- The UCL-Hatter Cardiovascular Institute's 6th International Cardioprotection Workshop convened to address the translation gap.
- The workshop generated the "Hatter Workshop Recommendations" to guide future research.
- These recommendations focus on optimizing both preclinical and clinical study methodologies.
Implementation:
- Enhancing the relevance and accuracy of animal models for ischemia-reperfusion injury.
- Establishing rigorous standards for the design and execution of clinical cardioprotection trials.
- Promoting collaboration between basic science researchers and clinical investigators.
Implications:
- Facilitating the successful translation of novel cardioprotective therapies from bench to bedside.
- Improving clinical outcomes for patients suffering from ischemic heart disease.
- Accelerating the development of effective treatments to combat the global burden of IHD.
Abstract:
Ischemic heart disease (IHD) is the leading cause of death worldwide. Novel cardioprotective strategies are therefore required to improve clinical outcomes in patients with IHD. Although a large number of novel cardioprotective strategies have been discovered in the research laboratory, their translation to the clinical setting has been largely disappointing. The reason for this failure can be attributed to a number of factors including the inadequacy of the animal ischemia-reperfusion injury models used in the preclinical cardioprotection studies and the inappropriate design and execution of the clinical cardioprotection studies. This important issue was the main topic of discussion of the UCL-Hatter Cardiovascular Institute 6th International Cardioprotection Workshop, the outcome of which has been published in this article as the "Hatter Workshop Recommendations". These have been proposed to provide guidance on the design and execution of both preclinical and clinical cardioprotection studies in order to facilitate the translation of future novel cardioprotective strategies for patient benefit.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Atherosclerosis III: Management
Heart Failure VI: Adjunct Therapies
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management

